Literature DB >> 27714485

A Pilot Study of Fragile X Syndrome Screening in Pregnant Women and Women Planning Pregnancy: Implementation, Acceptance, Awareness, and Geographic Factors.

Ramona Alfaro Arenas1,2, Jordi Rosell Andreo3,4,5, Damián Heine Suñer6,7,8,9.   

Abstract

We report herein results of a study performed in the Balearic Islands which had the following goals: 1) Determine the proportion of pregnant or non-pregnant women planning pregnancy, who would choose to undergo a screening test for Fragile X Syndrome (FXS), if it is accompanied by the appropriate information; 2) Assess satisfaction and any increase in stress among women who participate in screening; 3) Collect epidemiological information about the incidence of the disease in our population; and 4) Collect demographic and health history data and assess participants' awareness of the disease. Screening was performed on 3,731 pregnant and non-pregnant women of childbearing age and the results indicate: a very high voluntary rate of participation; a high level of self-reported satisfaction and low levels of stress because of the test; a very high incidence of premutation (1/106) in our population; and a low level of awareness about the existence of FXS (25 %). Additional findings indicate no significant correlation between self-reported health history and premutation detection, and the high premutation incidence does not seem to be specific to the indigenous Balearic population. Based on these results, we discuss the pros and cons of an implementation of preconception and pregnant women screening for FXS within a public health screening program.

Entities:  

Keywords:  Awareness; Fragile X syndrome; Intellectual disability; Neurogenetic disorder; Reproductive genetics; Satisfaction; Screening; Stress

Mesh:

Year:  2016        PMID: 27714485     DOI: 10.1007/s10897-016-0005-3

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  21 in total

1.  Prevalence of CGG expansions of the FMR1 gene in a US population-based sample.

Authors:  Marsha Mailick Seltzer; Mei Wang Baker; Jinkuk Hong; Matthew Maenner; Jan Greenberg; Daniel Mandel
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2012-05-22       Impact factor: 3.568

2.  Two-sided confidence intervals for the single proportion: comparison of seven methods.

Authors:  R G Newcombe
Journal:  Stat Med       Date:  1998-04-30       Impact factor: 2.373

Review 3.  Epidemiology of fragile X syndrome: a systematic review and meta-analysis.

Authors:  Jessica Hunter; Oliver Rivero-Arias; Angel Angelov; Edward Kim; Iain Fotheringham; Jose Leal
Journal:  Am J Med Genet A       Date:  2014-04-03       Impact factor: 2.802

4.  Validation of a screening tool for the rapid and reliable detection of CGG trinucleotide repeat expansions in FMR1.

Authors:  Monica J Basehore; Natalia M Marlowe; Julie R Jones; Deborah E Behlendorf; Thomas A Laver; Michael J Friez
Journal:  Genet Test Mol Biomarkers       Date:  2012-01-06

5.  Attitudes toward prenatal testing and pregnancy termination among a diverse population of parents of children with intellectual disabilities.

Authors:  Miriam Kuppermann; Sanae Nakagawa; Shana Raquel Cohen; Irenka Dominguez-Pareto; Brian L Shaffer; Susan D Holloway
Journal:  Prenat Diagn       Date:  2011-10-26       Impact factor: 3.050

6.  Fragile-X carrier screening and the prevalence of premutation and full-mutation carriers in Israel.

Authors:  H Toledano-Alhadef; L Basel-Vanagaite; N Magal; B Davidov; S Ehrlich; V Drasinover; E Taub; G J Halpern; N Ginott; M Shohat
Journal:  Am J Hum Genet       Date:  2001-07-06       Impact factor: 11.025

7.  Fragile X AGG analysis provides new risk predictions for 45-69 repeat alleles.

Authors:  Sarah L Nolin; Sachin Sah; Anne Glicksman; Stephanie L Sherman; Emily Allen; Elizabeth Berry-Kravis; Flora Tassone; Carolyn Yrigollen; Amy Cronister; Marcia Jodah; Nicole Ersalesi; Carl Dobkin; W Ted Brown; Raghav Shroff; Gary J Latham; Andrew G Hadd
Journal:  Am J Med Genet A       Date:  2013-02-26       Impact factor: 2.802

8.  AGG interruptions within the maternal FMR1 gene reduce the risk of offspring with fragile X syndrome.

Authors:  Carolyn M Yrigollen; Blythe Durbin-Johnson; Louise Gane; David L Nelson; Randi Hagerman; Paul J Hagerman; Flora Tassone
Journal:  Genet Med       Date:  2012-04-12       Impact factor: 8.822

Review 9.  A systematic review of population screening for fragile X syndrome.

Authors:  Melissa K Hill; Alison D Archibald; Jonathan Cohen; Sylvia A Metcalfe
Journal:  Genet Med       Date:  2010-07       Impact factor: 8.822

10.  FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States.

Authors:  Flora Tassone; Ka Pou Iong; Tzu-Han Tong; Joyce Lo; Louise W Gane; Elizabeth Berry-Kravis; Danh Nguyen; Lisa Y Mu; Jennifer Laffin; Don B Bailey; Randi J Hagerman
Journal:  Genome Med       Date:  2012-12-21       Impact factor: 11.117

View more
  2 in total

1.  Informed decision making and psychosocial outcomes in pregnant and nonpregnant women offered population fragile X carrier screening.

Authors:  Sylvia A Metcalfe; Melissa Martyn; Alice Ames; Vicki Anderson; Alison D Archibald; Grad Dip Gen Couns; Rob Carter; Jonathan Cohen; Megan Cotter; M GenCouns; William Dang; Martin B Delatycki; Susan Donath; Samantha Edwards; PGrad Dip Educ; Grad Dip Gen Couns; Robin Forbes; Grad Dip Gen Couns; Mioara Gavrila; M MedSci; Jane Halliday; Chriselle Hickerton; Melissa Hill; Grad Dip Gen Couns; Lorilli Jacobs; PGrad Dip Ultrasound; Vicki Petrou; Grad Dip Gen Couns; Loren Plunkett; M GenCouns; Leslie Sheffield; F Racp; Alison Thornton; Grad Dip Gen Couns; Sandra Younie; PGrad Dip Hlth Econ; Jon D Emery
Journal:  Genet Med       Date:  2017-06-29       Impact factor: 8.822

2.  Implementation of fragile X syndrome carrier screening during prenatal diagnosis: A pilot study at a single center.

Authors:  Hui Xi; Wanqin Xie; Jing Chen; Wanglan Tang; Xiuli Deng; Hua Li; Ying Peng; Dan Wang; Shuting Yang; Yanan Zhang; Ranhui Duan; Junqun Fang; Hua Wang
Journal:  Mol Genet Genomic Med       Date:  2021-05-31       Impact factor: 2.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.